Concepts (94)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neutropenia | 2 | 2021 | 968 | 1.090 |
Why?
|
| Maltose | 1 | 2021 | 22 | 0.800 |
Why?
|
| Hypophosphatemia | 1 | 2021 | 26 | 0.790 |
Why?
|
| Phosphorus | 1 | 2021 | 65 | 0.780 |
Why?
|
| Pancytopenia | 1 | 2021 | 120 | 0.770 |
Why?
|
| Ferric Compounds | 1 | 2021 | 73 | 0.760 |
Why?
|
| Autoimmune Diseases | 2 | 2021 | 402 | 0.710 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2021 | 128 | 0.660 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 573 | 0.500 |
Why?
|
| Bacteremia | 1 | 2019 | 689 | 0.470 |
Why?
|
| Thrombocytopenia | 3 | 2022 | 846 | 0.400 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 2 | 2022 | 110 | 0.390 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 2 | 2021 | 46 | 0.360 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 2 | 2020 | 67 | 0.340 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2021 | 2796 | 0.310 |
Why?
|
| Child, Preschool | 8 | 2021 | 16273 | 0.250 |
Why?
|
| Musculoskeletal Abnormalities | 1 | 2024 | 82 | 0.230 |
Why?
|
| Upper Extremity Deformities, Congenital | 1 | 2022 | 6 | 0.220 |
Why?
|
| UDPglucose 4-Epimerase | 1 | 2021 | 8 | 0.200 |
Why?
|
| Galactosemias | 1 | 2021 | 17 | 0.200 |
Why?
|
| May-Thurner Syndrome | 1 | 2021 | 5 | 0.200 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2021 | 6915 | 0.200 |
Why?
|
| Congenital Disorders of Glycosylation | 1 | 2021 | 37 | 0.190 |
Why?
|
| Child | 12 | 2024 | 29154 | 0.190 |
Why?
|
| Infant | 6 | 2021 | 13310 | 0.180 |
Why?
|
| Hydroxyurea | 1 | 2020 | 204 | 0.180 |
Why?
|
| Coombs Test | 1 | 2019 | 17 | 0.170 |
Why?
|
| Rho(D) Immune Globulin | 1 | 2019 | 15 | 0.170 |
Why?
|
| Infusions, Intravenous | 1 | 2021 | 1382 | 0.160 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2019 | 180 | 0.160 |
Why?
|
| Venous Thrombosis | 1 | 2021 | 384 | 0.150 |
Why?
|
| Rheumatic Diseases | 1 | 2017 | 54 | 0.150 |
Why?
|
| Maximum Tolerated Dose | 1 | 2020 | 1290 | 0.150 |
Why?
|
| Anemia, Sickle Cell | 1 | 2020 | 339 | 0.140 |
Why?
|
| Adolescent | 10 | 2022 | 31252 | 0.140 |
Why?
|
| Intellectual Disability | 1 | 2024 | 1032 | 0.140 |
Why?
|
| Hematologic Diseases | 1 | 2017 | 242 | 0.140 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 544 | 0.130 |
Why?
|
| Thromboembolism | 1 | 2016 | 155 | 0.130 |
Why?
|
| Age Factors | 2 | 2021 | 5377 | 0.120 |
Why?
|
| Female | 13 | 2022 | 141928 | 0.120 |
Why?
|
| Hemoglobin C | 1 | 2013 | 5 | 0.110 |
Why?
|
| Retrospective Studies | 6 | 2021 | 37905 | 0.110 |
Why?
|
| Male | 11 | 2021 | 123000 | 0.110 |
Why?
|
| Hemoglobinopathies | 1 | 2013 | 24 | 0.110 |
Why?
|
| Humans | 17 | 2024 | 261506 | 0.110 |
Why?
|
| Rituximab | 1 | 2017 | 1528 | 0.100 |
Why?
|
| Young Adult | 3 | 2021 | 21445 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 14889 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2020 | 1819 | 0.060 |
Why?
|
| Anticoagulants | 2 | 2021 | 787 | 0.060 |
Why?
|
| Islets of Langerhans | 1 | 2004 | 229 | 0.050 |
Why?
|
| Radius | 1 | 2022 | 42 | 0.050 |
Why?
|
| Mammals | 1 | 2024 | 361 | 0.050 |
Why?
|
| Prognosis | 1 | 2019 | 21713 | 0.050 |
Why?
|
| Glycolipids | 1 | 2021 | 58 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 355 | 0.050 |
Why?
|
| Polysaccharides | 1 | 2021 | 197 | 0.050 |
Why?
|
| Transcription Factors | 2 | 2024 | 5270 | 0.040 |
Why?
|
| Phenotype | 2 | 2021 | 6295 | 0.040 |
Why?
|
| Developmental Disabilities | 1 | 2024 | 674 | 0.040 |
Why?
|
| Drosophila | 1 | 2024 | 839 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2024 | 1152 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2004 | 1143 | 0.040 |
Why?
|
| Prenatal Diagnosis | 1 | 2022 | 590 | 0.040 |
Why?
|
| Disease Management | 1 | 2021 | 1052 | 0.030 |
Why?
|
| Erythrocyte Indices | 1 | 2013 | 24 | 0.030 |
Why?
|
| Hemoglobins, Abnormal | 1 | 2013 | 19 | 0.030 |
Why?
|
| beta-Thalassemia | 1 | 2013 | 17 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2004 | 4078 | 0.030 |
Why?
|
| Adult | 4 | 2021 | 77950 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 3260 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2022 | 6150 | 0.030 |
Why?
|
| Erythrocytes | 1 | 2013 | 339 | 0.030 |
Why?
|
| Neoplasms | 1 | 2017 | 15193 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2017 | 2803 | 0.020 |
Why?
|
| Homozygote | 1 | 2013 | 717 | 0.020 |
Why?
|
| Point Mutation | 1 | 2013 | 769 | 0.020 |
Why?
|
| Heterozygote | 1 | 2013 | 1020 | 0.020 |
Why?
|
| Comorbidity | 1 | 2016 | 2352 | 0.020 |
Why?
|
| Pregnancy | 1 | 2022 | 7573 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2020 | 8223 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6207 | 0.020 |
Why?
|
| Paired Box Transcription Factors | 1 | 2004 | 134 | 0.010 |
Why?
|
| Zebrafish Proteins | 1 | 2004 | 163 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2017 | 12873 | 0.010 |
Why?
|
| Animals | 2 | 2024 | 59536 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2004 | 1037 | 0.010 |
Why?
|
| Mutation | 1 | 2021 | 15179 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2021 | 32848 | 0.010 |
Why?
|
| Risk Factors | 1 | 2016 | 17523 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2004 | 5710 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 7548 | 0.010 |
Why?
|
| Mice | 1 | 2004 | 34495 | 0.000 |
Why?
|